MUMBAI, India, July 24 -- Intellectual Property India has published a patent application (202647086674 A) filed by Sichuan Huiyu Pharmaceutical Co. , Ltd.; and Sichuan Huiyu Seacross Pharmaceutical on July 15, 2026, for Bispecific Antibody-Cytokine Fusion Protein And Use Thereof.
Inventors include Zheng, Xuan; Ding, Zhao; Wei, Tao; Chen, Yan Number; Dong, Guibin; Li, Chunxia; Zhan, Jinxi; and Yang, Liu.
The application for the patent was published on July 17, 2026, under issue no. 29/2026.
Abstract: Provided is a bispecific antibody-cytokine fusion protein. Specifically provided is a bispecific antibody-cytokine fusion protein targeting to TIGIT and PD-1 and having immune effector cell activation effect. The bispecific antibody-cytokine fusion protein has good medication safety and anti-tumor effect. Also provided is the use of the bispecific antibody-cytokine fusion protein in disease treatment.
Disclaimer: Curated by HT Syndication.
